BH.IMMUN&BIO | LINK PHARMA | BH.IMMUN&BIO/ LINK PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -7.7 | -10.7 | - | View Chart |
P/BV | x | 1.5 | 1.3 | 116.3% | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
BH.IMMUN&BIO LINK PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BH.IMMUN&BIO Mar-23 |
LINK PHARMA Mar-23 |
BH.IMMUN&BIO/ LINK PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 52 | 75 | 69.1% | |
Low | Rs | 21 | 35 | 58.5% | |
Sales per share (Unadj.) | Rs | 10.3 | 87.3 | 11.8% | |
Earnings per share (Unadj.) | Rs | -3.9 | 1.5 | -261.6% | |
Cash flow per share (Unadj.) | Rs | -3.8 | 3.6 | -107.2% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 20.4 | 33.9 | 60.3% | |
Shares outstanding (eoy) | m | 43.18 | 4.44 | 972.5% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.5 | 0.6 | 555.0% | |
Avg P/E ratio | x | -9.4 | 37.3 | -25.1% | |
P/CF ratio (eoy) | x | -9.5 | 15.5 | -61.3% | |
Price / Book Value ratio | x | 1.8 | 1.6 | 108.9% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 1,561 | 244 | 638.8% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 151 | 57 | 266.2% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 446 | 388 | 115.1% | |
Other income | Rs m | 11 | 3 | 407.7% | |
Total revenues | Rs m | 457 | 390 | 117.0% | |
Gross profit | Rs m | -161 | 23 | -695.3% | |
Depreciation | Rs m | 2 | 9 | 21.7% | |
Interest | Rs m | 71 | 8 | 927.7% | |
Profit before tax | Rs m | -223 | 9 | -2,513.3% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -56 | 2 | -2,426.3% | |
Profit after tax | Rs m | -166 | 7 | -2,544.2% | |
Gross profit margin | % | -36.0 | 6.0 | -604.2% | |
Effective tax rate | % | 25.3 | 26.2 | 96.5% | |
Net profit margin | % | -37.3 | 1.7 | -2,209.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 358 | 175 | 204.0% | |
Current liabilities | Rs m | 940 | 145 | 647.9% | |
Net working cap to sales | % | -130.6 | 7.8 | -1,667.2% | |
Current ratio | x | 0.4 | 1.2 | 31.5% | |
Inventory Days | Days | 85 | 56 | 153.6% | |
Debtors Days | Days | 1,135 | 342 | 332.1% | |
Net fixed assets | Rs m | 1,262 | 149 | 846.4% | |
Share capital | Rs m | 432 | 44 | 972.3% | |
"Free" reserves | Rs m | 450 | 106 | 424.9% | |
Net worth | Rs m | 882 | 150 | 586.6% | |
Long term debt | Rs m | 0 | 20 | 0.0% | |
Total assets | Rs m | 1,620 | 325 | 499.1% | |
Interest coverage | x | -2.2 | 2.2 | -99.5% | |
Debt to equity ratio | x | 0 | 0.1 | 0.0% | |
Sales to assets ratio | x | 0.3 | 1.2 | 23.1% | |
Return on assets | % | -5.9 | 4.4 | -135.6% | |
Return on equity | % | -18.9 | 4.4 | -433.6% | |
Return on capital | % | -17.2 | 9.7 | -178.1% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 14.5 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 65 | NA | - | |
Fx inflow | Rs m | 0 | 0 | - | |
Fx outflow | Rs m | 65 | 0 | - | |
Net fx | Rs m | -65 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 109 | -17 | -638.1% | |
From Investments | Rs m | 5 | -1 | -616.0% | |
From Financial Activity | Rs m | -147 | 16 | -914.9% | |
Net Cashflow | Rs m | -34 | -2 | 1,929.3% |
Indian Promoters | % | 59.3 | 51.5 | 115.1% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 0.0 | - | |
FIIs | % | 0.0 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 40.8 | 48.5 | 84.0% | |
Shareholders | 35,313 | 6,200 | 569.6% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BH.IMMUN&BIO With: DIVIS LABORATORIES SUN PHARMA CIPLA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | BH.IMMUN&BIO | LINK PHARMA | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -2.23% | -2.38% | 0.31% |
1-Month | -2.23% | -3.75% | 0.08% |
1-Year | 28.97% | 9.62% | 54.11% |
3-Year CAGR | -13.27% | 10.61% | 14.46% |
5-Year CAGR | 30.36% | 15.48% | 20.04% |
* Compound Annual Growth Rate
Here are more details on the BH.IMMUN&BIO share price and the LINK PHARMA share price.
Moving on to shareholding structures...
The promoters of BH.IMMUN&BIO hold a 59.3% stake in the company. In case of LINK PHARMA the stake stands at 51.5%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of BH.IMMUN&BIO and the shareholding pattern of LINK PHARMA.
Finally, a word on dividends...
In the most recent financial year, BH.IMMUN&BIO paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
LINK PHARMA paid Rs 0.0, and its dividend payout ratio stood at 0.0%.
You may visit here to review the dividend history of BH.IMMUN&BIO, and the dividend history of LINK PHARMA.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on positive note, Indian share markets continued the momentum as the session progressed and ended higher.